📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Embera NeuroTherapeutics

1.1 - Company Overview

Embera NeuroTherapeutics Logo

Embera NeuroTherapeutics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of development-stage pharmaceutical therapies for smoking cessation and other addictions with limited or no approved treatments. Developing EMB-001, a patented combination of metyrapone and oxazepam targeting complementary brain pathways and moderating activity in the stress response system. Completed Phase 1 studies in smokers; Phase 2 ongoing in cocaine use disorder and smoking cessation.

Products and services

  • EMB-001: A patented combination product comprised of metyrapone and oxazepam, targeting multiple pathways to potentially treat addictions by moderating activity in the stress response system
  • Phase 2 Clinical Studies: Ongoing Phase 2 studies for EMB-001 in cocaine use disorder and smoking cessation, funded by Series B financing and grant awards
  • Phase 1 Clinical Studies: Completed Phase 1 studies assessing safety, tolerability, and pharmacokinetics of EMB-001 in smokers, showing promising results for further development

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Embera NeuroTherapeutics

Plex Pharmaceuticals Logo

Plex Pharmaceuticals

HQ: United States Website
  • Description: Provider of therapeutics for neurodegenerative disorders and CNS tumors, including modulators of heat shock proteins and FK506 Binding Protein for ALS and Parkinson's disease, dual HSP90/TRAP1 inhibitors for glioblastoma, and non-surgical cataract treatments; enabled by a core platform that combines functional fragment screening with X-ray crystallography and a proprietary fragment library to identify and evolve drug leads.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Plex Pharmaceuticals company profile →
Lineagen Logo

Lineagen

HQ: United States Website
  • Description: Provider of diagnostic and healthcare services for complex genetic diseases, offering FirstStepDx PLUS chromosomal microarray to identify genomic deletions/duplications associated with autism spectrum disorder, developmental delay, intellectual disability, congenital anomalies, dysmorphic features, and epilepsy; NextStepDx PLUS whole exome sequencing; genetic counseling; and optical genome mapping data services.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Lineagen company profile →
Adamas Pharma Logo

Adamas Pharma

HQ: United States Website
  • Description: Provider of controlled and extended-release combination therapeutics for infectious diseases and central nervous system disorders, including products for symptomatic treatment of dementia. Offerings include Qelbree for ADHD; Trokendi XR and Oxtellar XR for epilepsy and migraine prevention; and candidates SPN-830 (hypomobility in Parkinson’s disease), SPN-820/821 (treatment-resistant depression), SPN-817 (severe epilepsy).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Adamas Pharma company profile →
NeuroPace Logo

NeuroPace

HQ: United States Website
  • Description: Provider of implantable neurostimulation devices for neurological disorders, featuring the FDA-approved RNS System for epilepsy to monitor brain activity, detect unusual patterns, and deliver responsive pulses to prevent seizures. Offers personalized neuromodulation based on patient brain activity, the nSight platform for remote data access, and clinical studies (NAUTILUS, RESPONSE, and other RNS System trials).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NeuroPace company profile →
PaxMedica Logo

PaxMedica

HQ: United States Website
  • Description: Provider of biopharmaceutical therapies addressing neurodevelopmental disorders, including PAX-101 for early-stage East African Human African Trypanosomiasis and PAX-101 under development for Autism Spectrum Disorder. Conducts clinical trials evaluating suramin in ASD and collaborates on translational research to support research leading to FDA-approved treatments for autism comorbidities.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full PaxMedica company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Embera NeuroTherapeutics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Embera NeuroTherapeutics

2.2 - Growth funds investing in similar companies to Embera NeuroTherapeutics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Embera NeuroTherapeutics

4.2 - Public trading comparable groups for Embera NeuroTherapeutics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Embera NeuroTherapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Embera NeuroTherapeutics

What does Embera NeuroTherapeutics do?

Embera NeuroTherapeutics is a provider of development-stage pharmaceutical therapies for smoking cessation and other addictions with limited or no approved treatments. Developing EMB-001, a patented combination of metyrapone and oxazepam targeting complementary brain pathways and moderating activity in the stress response system. Completed Phase 1 studies in smokers; Phase 2 ongoing in cocaine use disorder and smoking cessation.

Who are Embera NeuroTherapeutics's competitors?

Embera NeuroTherapeutics's competitors and similar companies include Plex Pharmaceuticals, Lineagen, Adamas Pharma, NeuroPace, and PaxMedica.

Where is Embera NeuroTherapeutics headquartered?

Embera NeuroTherapeutics is headquartered in United States.

How many employees does Embera NeuroTherapeutics have?

Embera NeuroTherapeutics has 1,000 employees 🔒.

When was Embera NeuroTherapeutics founded?

Embera NeuroTherapeutics was founded in 2010 🔒.

What sector and industry vertical is Embera NeuroTherapeutics in?

Embera NeuroTherapeutics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Embera NeuroTherapeutics

Who are the top strategic acquirers in Embera NeuroTherapeutics's sector and industry

Top strategic M&A buyers and acquirers in Embera NeuroTherapeutics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Embera NeuroTherapeutics?

Top strategic M&A buyers groups and sectors for Embera NeuroTherapeutics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Embera NeuroTherapeutics's sector and industry vertical

Which are the top PE firms investing in Embera NeuroTherapeutics's sector and industry vertical?

Top PE firms investing in Embera NeuroTherapeutics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Embera NeuroTherapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Embera NeuroTherapeutics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Embera NeuroTherapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Embera NeuroTherapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Embera NeuroTherapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Embera NeuroTherapeutics?

The key public trading comparables and valuation benchmarks for Embera NeuroTherapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Embera NeuroTherapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Embera NeuroTherapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Embera NeuroTherapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Embera NeuroTherapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Embera NeuroTherapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Embera NeuroTherapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Embera NeuroTherapeutics